News Focus
News Focus
icon url

MahinAgency

10/23/24 3:39 PM

#196 RE: Tiger Money #188

NASDAQ: $CRDL Promising clinical progress: Ongoing Phase II trials for myocarditis and pericarditis, with major data expected November 2024

Time to Add $CRDL Big wave coming
Bullish
Bullish
icon url

MahinAgency

10/25/24 12:42 PM

#201 RE: Tiger Money #188

NASDAQ: $CRDL H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.

CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.
Bullish
Bullish